[{"id":"5de3ae22-f200-40ed-bea2-6427c55b3ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984328","created_at":"2025-06-07T14:42:38.975Z","updated_at":"2025-06-07T14:42:38.975Z","phase":"Phase 2","brief_title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","source_id_and_acronym":"NCT06984328","lead_sponsor":"Genmab","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2029","study_completion_date":" 07/15/2029","last_update_posted":"2025-06-03"},{"id":"30f65fb4-2749-4fef-afce-463eb9f18dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046274","created_at":"2023-09-21T15:11:03.332Z","updated_at":"2024-07-02T16:35:06.914Z","phase":"Phase 2","brief_title":"GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer","source_id_and_acronym":"NCT06046274","lead_sponsor":"Genmab","biomarkers":" MSI • TIGIT","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-04-30"}]